Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects

AIM: Amiselimod (MT‐1303) is a selective sphingosine 1‐phosphate 1 (S1P(1)) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical,...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Tomohiko, Wilbraham, Darren, de La Borderie, Guillemette, Inoue, Shinsuke, Bush, Jim, Camm, A. John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401982/
https://www.ncbi.nlm.nih.gov/pubmed/27921320
http://dx.doi.org/10.1111/bcp.13203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401982/
https://www.ncbi.nlm.nih.gov/pubmed/27921320
http://dx.doi.org/10.1111/bcp.13203

Ejemplares similares